SelecTech Reports Stony Brook University Goes FreeStyle with Installation of BioLock tiles at New Lab

SelecTech, Inc., a leader in the manufacture of innovative flooring products with long-term value and immediate benefits, recently announced the completion of the installation of its FreeStyle BioLock tiles at a new lab at Stony Brook University in Stony Brook, New York. The Stony Brook University facilities team installed the flooring.

Two thousand square feet of FreeStyle BioLock tiles were installed in a new lab in the school’s Research and Development Park building. The lab will open this spring.

“Like many schools and universities, Stony Brook is trying to meet the demand for additional lab space. Also like many schools, they are converting existing space. Our interlocking product is the perfect solution for this scenario as it can be installed over existing flooring with little or no remediation,” said Thomas Ricciardelli, president of SelecTech, Inc. “This benefits the school should there be an expansion or relocation of the lab in the future as our interlocking tiles are transportable.”

The transportability of the tiles comes from a patented glueless “zipper” interlocking system that enables the flooring to be installed over existing flooring with minimal subfloor preparation. There’s no need for messy, toxic adhesive and down-time is significantly reduced—often times without need to close off an area.

In addition to the installation benefits, BioLock utilizes a water-proof seam sealer that makes tiles liquid-tight but still removable and replaceable. This modular benefit prevents liquids from penetrating the seams and getting below the floor, contributing to the prevention of the growth of infectious organisms—an extremely important factor for labs. With its urethane, no-wax finish, the commercial grade BioLock is extremely easy to maintain.

Made with 70 percent recycled materials and 100 percent recyclable, BioLock meets CA 1350 Indoor Air Quality and is MAS Certified Green.

“BioLock also offers ergonomic benefits as its far more comfortable to stand and walk on and also has sound reduction qualities,” said Ricciardelli.

FreeStyle BioLock is available in six stock colors and 30 special order colors.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version